Clinical Trial Update: CC-486 and Venetoclax for Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CC-486 (oral azacitidine) in combination with venetoclax for acute myeloid leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CC-486 (azacitidine)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Colorado, Denver | Conditions: AML | Phase 1 | Status: RECRUITING